EQRx, Inc. (NASDAQ:EQRX – Get Rating) saw an uptick in trading volume on Monday . 148,720 shares traded hands during mid-day trading, a decline of 92% from the previous session's volume of 1,765,429 shares.The stock last traded at $5.34 and had previously closed at $5.14.
Analysts Set New Price Targets
A number of research firms have weighed in on EQRX. JPMorgan Chase & Co. began coverage on shares of EQRx in a research note on Tuesday, August 16th. They issued a "neutral" rating and a $5.50 target price on the stock. The Goldman Sachs Group started coverage on shares of EQRx in a research note on Monday, June 13th. They set a "buy" rating and a $8.00 price target on the stock. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $6.37.
Get
EQRx alerts:
EQRx Stock Performance
The stock's 50 day moving average is $5.09 and its 200 day moving average is $4.57.
Institutional Trading of EQRx
Institutional investors have recently modified their holdings of the business. Pictet Asset Management SA bought a new stake in EQRx during the 2nd quarter worth approximately $49,000. Prudential Financial Inc. bought a new stake in EQRx during the 2nd quarter worth approximately $53,000. Exos Asset Management LLC bought a new stake in EQRx during the 4th quarter worth approximately $59,000. Virtu Financial LLC bought a new stake in EQRx during the 1st quarter worth approximately $64,000. Finally, Advisor Group Holdings Inc. bought a new stake in EQRx during the 4th quarter worth approximately $67,000. 80.38% of the stock is currently owned by hedge funds and other institutional investors.
EQRx Company Profile
(Get Rating)
EQRx, Inc, a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); and Sugemalimab, an anti-programmed death-ligand 1 antibody for the treatment of Stage III and Stage IV NSCLC.
Featured Articles
- Get a free copy of the StockNews.com research report on EQRx (EQRX)
- This Is What To Expect From The Q3 Earnings Reporting Season
- 3 Biotech Stocks Gaining Momentum
- Can Electronic Arts Buck the Downturn in Videogaming?
- Dollar General is the Big Fish in Little Ponds Across the U.S.
- Here's Why the CPI Report will Dictate the Market Bottom
Receive News & Ratings for EQRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EQRx and related companies with MarketBeat.com's FREE daily email newsletter.
EQRx, Inc. (NASDAQ:EQRX – Get Rating) saw an uptick in trading volume on Monday . 148,720 shares traded hands during mid-day trading, a decline of 92% from the previous session's volume of 1,765,429 shares.The stock last traded at $5.34 and had previously closed at $5.14.
EQRx, Inc.（納斯達克：EQRX — 獲得評級）週一 148,720 股在中期交易手中交易手的股票，較上一個交易時段交易量 1,765,429 股下降了 92%。該股票最後交易價為 5.34 美元，之前已收盤於 5.14 美元。
Analysts Set New Price Targets
A number of research firms have weighed in on EQRX. JPMorgan Chase & Co. began coverage on shares of EQRx in a research note on Tuesday, August 16th. They issued a "neutral" rating and a $5.50 target price on the stock. The Goldman Sachs Group started coverage on shares of EQRx in a research note on Monday, June 13th. They set a "buy" rating and a $8.00 price target on the stock. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $6.37.
一些研究公司已經對 EQRX 進行了稱重。摩根大通公司於 8 月 16 日（星期二）在一份研究報告中開始覆蓋 EQRx 的股份。他們對股票發出了「中性」評級和 5.50 美元的目標價。高盛集團於 6 月 13 日（星期一）在一份研究報告中開始對 EQRx 的股份進行報導。他們設定了「買入」評級和 8.00 美元的股票價格目標。一位研究分析師對該股票進行了持有評級，而四名研究分析師對該公司的股票分配了買入評級。根據 MarketBeat.com 的資料，該股票目前的平均評級為「適度買入」，共識目標價為 6.37 美元。
Get
EQRx
alerts:
EQRx Stock Performance
The stock's 50 day moving average is $5.09 and its 200 day moving average is $4.57.
該股票的 50 日移動平均線為 5.09 美元，其 200 日移動平均線為 4.57 美元。
Institutional Trading of EQRx
Institutional investors have recently modified their holdings of the business. Pictet Asset Management SA bought a new stake in EQRx during the 2nd quarter worth approximately $49,000. Prudential Financial Inc. bought a new stake in EQRx during the 2nd quarter worth approximately $53,000. Exos Asset Management LLC bought a new stake in EQRx during the 4th quarter worth approximately $59,000. Virtu Financial LLC bought a new stake in EQRx during the 1st quarter worth approximately $64,000. Finally, Advisor Group Holdings Inc. bought a new stake in EQRx during the 4th quarter worth approximately $67,000. 80.38% of the stock is currently owned by hedge funds and other institutional investors.
機構投資者最近修改了他們對業務的持有情況。百達資產管理 SA 在第二季度購買了 EQRx 的新股份，價值約為 49,000 美元。英國保誠金融股份有限公司在第二季度購入了 EQRx 的新股份，價值約為 $53,000。埃克索斯資產管理有限責任公司在第四季度購買了 EQRx 的新股份，價值約為 59,000 美元。維圖金融有限責任公司在第一季度購買了 EQRx 的新股份，價值約為 64,000 美元。最後，顧問集團控股有限公司在第四季度購買了價值約 67,000 美元的 EQRx 的新股份。80.38％ 的股票目前由對沖基金和其他機構投資者擁有。
EQRx Company Profile
EQRx, Inc, a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); and Sugemalimab, an anti-programmed death-ligand 1 antibody for the treatment of Stage III and Stage IV NSCLC.
EQRx, Inc. 是一家製藥公司，在美國從事主要用於治療腫瘤學和免疫炎症性疾病的藥物開發。該公司在 III 期臨床試驗中的預註冊計劃包括用於治療 EGFR 非小細胞肺癌（NSCLC）患者的表皮生長因子受體（EGFR）抑製劑 Aumolertinib；以及用於治療 III 期和 IV 期非小細胞肺癌患者的抗程式設計死亡配體 1 抗體 Sugemalimab。
Featured Articles
- Get a free copy of the StockNews.com research report on EQRx (EQRX)
- This Is What To Expect From The Q3 Earnings Reporting Season
- 3 Biotech Stocks Gaining Momentum
- Can Electronic Arts Buck the Downturn in Videogaming?
- Dollar General is the Big Fish in Little Ponds Across the U.S.
- Here's Why the CPI Report will Dictate the Market Bottom
- 獲取有關 EQRX（EQRX）研究報告的免費副本
- 這是第三季度盈利報告季節的期望
- 3 股生物技術股獲得動力
- 電子藝術可以降低視頻遊戲的衰退嗎？
- 美元一般是美國各地小池塘中的大魚。
- 這就是為什麼消費者價格指數報告將決定市場底部
Receive News & Ratings for EQRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EQRx and related companies with MarketBeat.com's FREE daily email newsletter.
接收 EQRx 每日新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 EQRx 及相關公司的最新新聞和分析師評級的簡要每日摘要。
